CoChat
Sign Up
Cited by 152T-cell and Retrovirus StudiesViral-associated cancers and disordersChronic Lymphocytic Leukemia Research

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002

Ishida, Takashi, Fujiwara, Hiroshi, Nosaka, Kisato, Taira, Naoya, Abe, Yasunobu, Imaizumi, Yoshitaka, Moriuchi, Yukiyoshi, Jo, Tatsuro, Ishizawa, Kenichi, Tobinai, Kensei, Tsukasaki, Kunihiro, Ito, Shigeki, Yoshimitsu, Makoto, Otsuka, Maki, Ogura, Michinori, Midorikawa, Shuichi, Ruiz, Wanda, Ohtsu, Tomoko·2016·Journal of Clinical Oncology
DOI 10.1200/jco.2016.67.7732
Open this paper in CoChat — free account

Abstract

Purpose: Few treatment options exist for adult T-cell leukemia/lymphoma (ATL), and the prognosis for this disease is poor. A phase I study of lenalidomide demonstrated preliminary antitumor activity in patients with relapsed ATL. The current phase II study evaluated the efficacy and safety of lenalidomide monotherapy in patients with relapsed or recurrent ATL. Patients and Methods: Patients 20 years of age or older with acute, lymphoma, or unfavorable chronic subtype ATL, who had received one or more prior anti-ATL systemic chemotherapy and achieved stable disease or better on their last anti-ATL therapy with subsequent relapse or recurrence, were eligible. Patients received oral lenalidomide 25 mg/d continuously until disease progression or unacceptable toxicity. The primary end point was overall response rate; secondary end points included safety, tumor control rate (stable disease or better), time to response, duration of response, time to progression, progression-free survival, and overall survival. Results: Objective responses were noted in 11 of 26 patients (overall response rate, 42%; 95% CI, 23% to 63%), including four complete responses and one unconfirmed complete response. The tumor control rate was 73%. The median time to response and duration of response were 1.9 months and not estimable, respectively, and the median time to progression was 3.8 months. The median progression-free survival and overall survival were 3.8 and 20.3 months, respectively. The most frequent grade ≥ 3 adverse events were neutropenia (65%), leukopenia (38%), lymphopenia (38%), and thrombocytopenia (23%), which were all manageable and reversible. Conclusion: Lenalidomide demonstrated clinically meaningful antitumor activity and an acceptable toxicity profile in patients with relapsed or recurrent aggressive ATL, hinting at its potential to become a treatment option. Further investigations of lenalidomide in ATL and other mature T-cell neoplasms are warranted.

Overview

Integrity signals

Registry

Crossref · 10.1200/jco.2016.67.7732

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 44 references

Cited by

Sorted by citations

Items 101–152 of 152

Related

See all

Metadata

Authors
Ishida, T., Fujiwara, H., Nosaka, K., Taira, N., Abe, Y., Imaizumi, Y., Moriuchi, Y., Jo, T., Ishizawa, K., Tobinai, K., Tsukasaki, K., Ito, S., Yoshimitsu, M., Otsuka, M., Ogura, M., Midorikawa, S., Ruiz, W., & Ohtsu, T.
Affiliations
Nagoya City University (JP)
ORCID
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
2016-12-01
Volume
34
Issue
34
Pages
4086-4093
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.2016.67.7732
OpenAlex
W2519997684
Cited by
152
References
44
Citations by year
2026: 7 · 2025: 16 · 2024: 9 · 2023: 13 · 2022: 13 · 2021: 24 · 2020: 21 · 2019: 16 · 2018: 18 · 2017: 15
FWCI
9.88
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Japan Society for the Promotion of Science (16H04713, 15K09506)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
  • Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
lenalidomide, adult T-cell leukemia/lymphoma, monotherapy, overall response rate, progression-free survival, neutropenia, adverse events, T-cell neoplasms
MeSH terms
Lenalidomide, Administration, Oral, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Prognosis, Recurrence, Remission Induction, Thalidomide, Leukemia-Lymphoma, Adult T-Cell, Survival Rate, Treatment Outcome, Disease Progression, Angiogenesis Inhibitors, Endpoint Determination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review